Keywords: EMA Recommendations, Nycomed, AstraZeneca, Novartis, Pfizer, Sanofi Pasteur, Takeda, Revestive, Zinforo, Seebri Breezhaler, Elelyso, Hexaxim, Ceftaroline
EMA backs approval of Revestive, Zinforo and Seebri Breezhaler, but not Elelyso; Hexaxim opinion
Article | 25 June 2012
Following meetings last week, the European Medicines Agency issued a number of recommendations and opinions regarding marketing authorization applications from ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
